3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
3
Recruiting
3
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
84
Ovarian Neoplasms
35
Breast Neoplasms
32
Lung Neoplasms
28
Uterine Cervical Neoplasms
18
Triple Negative Breast Neoplasms
15
Fallopian Tube Neoplasms
15
Carcinoma, Ovarian Epithelial
15
Small Cell Lung Carcinoma
13
Squamous Cell Carcinoma of Head and Neck
10
Neuroblastoma
10
Esophageal Neoplasms
10
Esophageal Squamous Cell Carcinoma
8
Central Nervous System Neoplasms
8
Recurrence
7
Head and Neck Neoplasms
6
Endometrial Neoplasms
6
Retinoblastoma
5
Neoplasm Metastasis
5
Brain Neoplasms
5
Adenocarcinoma of Lung
5
Neoplasms
4
Melanoma
4
Carcinoma, Squamous Cell
4
Testicular Neoplasms
3
Oligodendroglioma
3
Medulloblastoma
3
Lymphoma, Large B-Cell, Diffuse
3
Hodgkin Disease
3
Glioblastoma
3
Interventions
camrelizumab
2
apatinib
2
sintilimab
1
Vinorelbine
1
Pemetrexed
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Respiratory Tract Diseases
×
Carboplatin
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled